Sep 27 2011
YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.
A poster presentation entitled "Phase 2 study of nimotuzumab in combination with concurrent chemoradiotherapy (CRT) in patients with locally advanced non-small cell lung cancer (NSCLC)" is scheduled to be presented at the poster session "Lung Cancer-Localised/Local Regional" on Monday, September 26th, 2011 from 14:00 to 16:30pm (Abstract # 9044; Poster Board 033).
A poster presentation entitled "Nimotuzumab and Vinorelbine Concomitantly to Radiation and as Maintenance for Diffuse Pontine Glioma in Childhood: Promising Results on a Series of 13 Patients" is scheduled to be presented at the poster session "Paediatric Oncology" on Sunday, September 25th, 2011 from 14:00 to 16:30pm (Abstract # 4125; Poster Board 408).
A poster presentation entitled "Nimotuzumab in Combination with Chemotherapy in the Patients with Advanced Non-small Cell Lung Cancer" is scheduled to be presented at the poster session "Lung Cancer-Metastatic" on Monday, September 26th, 2011 from 14:00 to 16:30pm (Abstract # 9124; Poster Board 113).
A poster presentation entitled "Pilot Study of Target Therapy With EGFR Antibody (Nimotuzumab) in Patients With Unresectable Head and Neck Cancer" is scheduled to be presented at the poster session "Head and Neck Cancer" on Sunday, September 25th, 2011 from 9:30am to 12:00pm (Abstract # 8588; Poster Board 081).
New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer